Aplastic anemia (AA) Myelodysplastic syndromes (MDS)
Conditions
Interventions
None listed
Sponsors
Ministry of Health, Labor and Welfare (MHLW)
Executive manager for central review: Department of Hemato-Oncology, Saitama Medical University International Medical Center Practitioners for central review : Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Department of Hemato-Oncology, Saitama Medical University International Medical Center Department of Hematology, Kitasato University Department of Hematology, National Hospital Organization Kyoto Medical Center Department of Laboratory Medicine, Kawasaki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Newly diagnosed aplastic anemia and MDS, or cases with difficulties to distinguish between AA from MDS.
Exclusion criteria
Exclusion criteria: The case without documented consensus is excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The assessment including cellularity of bone marrow, presence and frequency of dysplasia, evaluation of other notable morphological findings, and morphologic diagnosis by central review. The evaluation of clinical outcomes under current treatment practice in Japan and of therapeutic efficacy by prospective registration program. | — |
Countries
Japan
Contacts
Public ContactJunya Kanda
Graduate School of Medicine, Kyoto University Faculty of Medicine, Department of Hematology and Oncology
Outcome results
None listed